Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress May 28, 2024 14:00 CET Non Regulatory Read more
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO’s Mode of Action May 16, 2024 16:30 CET Non Regulatory Read more
Invitation to the presentation of Calliditas´s interim report January – March 2024 May 16, 2024 08:30 CET Non Regulatory Read more
Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm May 15, 2024 14:00 CET Non Regulatory Read more
Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China May 14, 2024 13:00 CET Non Regulatory Read more
Calliditas Announces Positive NefIgArd Open Label Extension Results April 24, 2024 08:30 CET Non Regulatory Read more
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 April 18, 2024 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to Attend Conferences in April April 9, 2024 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 – 16 in Buenos Aires April 8, 2024 14:00 CET Non Regulatory Read more
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment April 8, 2024 09:00 CET Non Regulatory Read more
Calliditas Therapeutics to Attend Investor Conferences in March March 1, 2024 13:00 CET Non Regulatory Read more
Invitation to the presentation of Calliditas´ Year-end report January – December 2023 February 14, 2024 07:00 CET Non Regulatory Read more
Calliditas Therapeutics appoints Maria Törnsén as President North America January 7, 2024 17:00 CET Non Regulatory Read more
Calliditas to present at JP Morgan Healthcare Conference January 7, 2024 15:00 CET Non Regulatory Read more